(3-Chloro-5-cyanophenyl)boronic acid

We are (3-Chloro-5-cyanophenyl)boronic acid CAS:915763-60-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

3-氰基-5-氯苯硼酸
Product Name: (3-Chloro-5-cyanophenyl)boronic acid
Other Name:
(3-Chloro-5-cyanophenyl)boronic acid
3-chloro-5-cyanophenylboronic acid
CAS No: 915763-60-9
MF: C7H5BClNO2
MW: 181.38400
Density: N/A
Boiling point: N/A
Melting point: N/A
Flash point: N/A
Refractive index: N/A
UN Number: Non-dangerous goods
Transport hazard class: Non-dangerous goods
Packing group: Non-dangerous goods
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

(3-Chloro-5-cyanophenyl)boronic acid


Related News: Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.4-(Difluoromethoxy)aniline CAS:22236-10-8 Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.392-83-6 Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.(3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.

Related Products
Product Name
Ethyl 5-bromovalerate View Details
3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid View Details
ethyl 2-amino-1,3-thiazole-5-carboxylate View Details
Octrizole manufacturer Quinoline-2,3-dicarboxylic acid manufacturer 2-Chloro-3,5-dinitrobenzotrifluoride manufacturer N-Methyl-N-(4-nitrophenethyl)-2-(4-nitrophenoxy)ethanamine manufacturer 9-Chlorononan-1-ol manufacturer